Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Motif Bio plc (MTFB) Ordinary 0.01p

Sell:0.50p Buy:0.50p 0 Change: No change
Market closed Prices as at close on 12 August 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:0.50p
Buy:0.50p
Change: No change
Market closed Prices as at close on 12 August 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:0.50p
Buy:0.50p
Change: No change
Market closed Prices as at close on 12 August 2020 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP). Iclaprim exhibits potent activity against Gram-positive clinical isolates of various genera of staphylococci. It intends to build a portfolio of antibiotics by licensing drug candidates from organizations specializing in antibacterial research, and is pursuing programs in various stages of development.

Contact details

Address:
1 Tudor Street
LONDON
EC4Y 0AH
United Kingdom
Telephone:
+ (0)
Website:
https://www.motifbio.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 30 September 2019 30/09/19

General stock information

EPIC:
MTFB
ISIN:
GB00BVVT4H71
Market cap:
£3.27 million
Shares in issue:
654.99 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Jonathan Gold
    President, Chief Financial Officer, Chief Business Officer
  • Stephanie Noviello
    Vice President - Clinical Development
  • Rajesh Shukla
    Vice President - Clinical Operations
  • David Huang
    Chief Medical Officer
  • Stephen Austin
    Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.